Novartis Acquires Excellergy for Up to $2 Billion Amid Patent Expirations

Novartis has announced an agreement to acquire U.S.-based biotech Excellergy for up to $2 billion, adding the early-stage drug candidate Exl-111 to its portfolio. This acquisition is part of Novartis' strategy to offset upcoming patent expirations that may lead to significant revenue losses. In the past week, Novartis also revealed a deal to acquire Pikavation Therapeutics for up to $3 billion. The transaction is expected to close in the first half of 2026, pending regulatory approval. Notably, Novartis shares have increased by 33% over the last 12 months.